Dr. Sequist Discusses Combination Regimens in EGFR+ NSCLC
Lecia V. Sequist, MD, associate professor of medicine, Harvard Medical School, Mary B. Saltonstall Chair, Oncology, Massachusetts General Hospital Center, discusses combination regimens for patients with EGFR-positive non-small cell lung cancer (NCSLC).
Lecia V. Sequist, MD, associate professor of medicine, Harvard Medical School, Mary B. Saltonstall Chair, Oncology, Massachusetts General Hospital Center, discusses combination regimens for patients with EGFR-positive non—small cell lung cancer (NCSLC).
Sequist says that one of the unique benefits of the third-generation agents having fewer adverse events is that there are more possibilities for combination regimens. In the past, frequently used agents such as erlotinib (Tarceva) or afatinib (Gilotrif) in combination with other therapies caused high rates of toxicities.
Moving forward, Sequist says that she is looking out for new trials with third-generation agents. There is potential in combinations of 2 EGFR-targeting drugs, or combinations with MET, JAK, or BRAF inhibitors. These combination trials will be done in the resistance setting or possibly the frontline setting, Sequist adds.
